Accendra Health Inc logo

Accendra Health Inc(ACH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.13
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ACH

11/13/2026: ACH (1-star) is currently NOT-A-BUY. Pass it for now.

Accendra Health Inc is a micro-cap healthcare distribution company delivering disposable medical supplies and home respiratory therapy through its Apria and Byram brands. Its primary business strength lies in its established nationwide reach addressing chronic care needs outside the hospital. The core investment opportunity rests on potential operational improvements from its home health focus and demographic tailwinds. However, severe risks include negative stockholders' equity, ongoing net losses, high volatility, and NYSE listing compliance notices. The stock suits speculative turnaround investors, requiring close monitoring of debt restructuring and liquidity metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitTop-line revenue is currently contracting, and the company is focused on operational turnaround rather than aggressive expansion.
Momentum investorMixed fitThe stock experiences severe short-term volatility, making it suitable only for aggressive tactical traders during brief oversold bounces.
Value investorWeak fitDeep balance sheet stress, negative stockholders' equity, and ongoing net losses outweigh low absolute share prices.
Dividend investorWeak fitThe company does not pay a dividend on its common stock.
Low-risk investorWeak fitHigh leverage, penny-stock trading levels, and listing compliance notices present severe capital preservation risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock trades at micro-cap levels with massive historical price swings and high beta.
Valuation riskHighNegative earnings and depressed book value make traditional valuation models highly speculative.
Competition risk (large medical distribution giants)Medium / highThe company competes against much larger, better-capitalized medical distributors.
Business qualityMediumWhile core home health brands have strong utility, corporate-level restructuring has impaired franchise stability.
Dividend incomeLow / noneNo dividend is paid to common shareholders.
Execution riskHighManagement must successfully execute turnaround plans and clear debt obligations to survive long-term.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.16M USD
Price to earnings Ratio -
1Y Target Price 1.2
Price to earnings Ratio -
1Y Target Price 1.2
Volume (30-day avg) 3.5M shares
Beta 1.62
52 Weeks Range 0.12 - 4.69
Updated Date 11/15/2026
52 Weeks Range 0.12 - 4.69
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.6

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Distribution

BUY participation
100.0%
Active BUY / eligible
3 / 3
30-Day BUY Count Change
+2

Eligible universe: 3 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -48.63%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ACH receives a 3-star rating based on the available scored pillars. The rating is constrained by soft unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ACH has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-203.5%), weak cash generation (FCF margin -11.0%), negative revenue growth (-74.2%).

Financial Health Rating

★★★★★
ACH's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 38.7% of revenue). Liquidity is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ACH's growth profile is soft, with the least-weak measure being revenue growth at -74.2% FY2025 versus FY2024. By comparison, while earnings growth (-203.5%, negative) and free-cash-flow growth (-354.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 83.6% and approximately 73.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.59% supports management-shareholder alignment.

Top 5 Institutional Investors

Coliseum Capital Management LLC 17.02%
BlackRock Inc 7.15%
Bank of America Corp 4.91%
Vanguard Capital Management, LLC 4.01%
D. E. Shaw & Co LP 4.00%

Unit Economics (Per $1K Revenue)

★★★★★
ACH generates approximately $467 of gross profit, $80 of operating income, and $-110 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Negative free cash flow explains the 2-star rating, with weak cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.72% (Tax Credit)

Quantitative Style Profile

★★★★★
ACH has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Home Medical EquipmentRental and sale of home respiratory therapy, oxygen equipment, and sleep apnea devices (CPAP/BiPAP).Generates recurring revenue from patients requiring ongoing respiratory care at home.
Disposable Medical SuppliesDirect home delivery of medical consumables for diabetes management, urology, wound care, and ostomy.Provides steady consumable-based cash flows backed by recurring patient reorders and insurance claims.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 6.94
Enterprise Value 1.80B
Price to Sales(TTM) -
Enterprise Value 1.80B
Price to Sales(TTM) -
Enterprise Value to Revenue 0.7
Enterprise Value to EBITDA 8.38
Shares Outstanding 76.97M
Shares Floating 56.18M
Shares Outstanding 76.97M
Shares Floating 56.18M
Percent Insiders 7.59
Percent Institutions 83.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.